THE ROLE OF CANDIDA IN INTESTINAL DYSBACTERIOSIS FORMATION

Area of Science:

• Microbiology
• Gastroenterology
• Infectious Diseases

Background:

• Tuberculosis (TB) chemotherapy is lengthy and essential for treatment.
• Prolonged TB treatment frequently leads to intestinal dysbiosis in a majority of patients (92%).
• Microbial imbalance in dysbiosis is characterized by bifidobacteria deficiency, facilitating Candida colonization.

Purpose of the Study:

• To investigate the role of Candida in the development of intestinal dysbacteriosis.
• To understand the impact of TB chemotherapy on gut microbiota.

Main Methods:

• Bacteriological examination of fecal samples was performed.
• The study involved 500 patients with various forms of pulmonary tuberculosis.
• The RV Epstein-Litvak FL Vilshanskoy method was used to detect intestinal dysbiosis.

Main Results:

• Intestinal dysbiosis was identified in 92% of patients undergoing long-term chemotherapy.
• A significant deficiency or absence of bifidobacteria was the primary microbial imbalance.
• Candida species played a major role in the altered microbial associations.
• Antifungal drugs demonstrated high therapeutic efficiency in eliminating Candida-associated intestinal dysbiosis.

Conclusions:

• Candida plays a significant role in the pathogenesis of intestinal dysbiosis during tuberculosis chemotherapy.
• Restoring the balance of gut microbiota, particularly bifidobacteria, is crucial.
• Antifungal therapy is effective in managing Candida overgrowth in TB patients with dysbiosis.